There is a compelling value proposition for ophthalmologists and optometrists, patients, contact lens manufacturers, pharmaceutical companies and payers
For contact lens manufacturers – OcuMedic’s solution leads to opportunities to license our technology and apply it to existing and new contact lens products thus extending their product lines to higher gross margin products typical in pharmaceuticals. OcuMedic also has technology that increases the comfort of contact lenses by releasing various comfort agents, which is the number one reason why contact lens users stop wearing lenses and the biggest problem facing contact lens manufacturers today, “patient drop-out!“ OcuMedic’s solution has relevant applications to improving contact lens wear comfort (i.e., eliminate dry eyes through extended release of comfort agents). Also, several contact lens manufacturers are subsidiaries of large pharmaceutical companies; therefore, opportunities exist to address additional consumer needs (e.g., corrective lenses and allergy) in an integrated solution with the potential for extended intellectual property coverage.
FOR PAYERS & INSURERS
For payers and Insurance companies they want therapeutic products that deliver a measurable reduction in health care costs. OcuMedic plans to structure its clinical trials so the economics of shorter recovery times and/or a reduction for the risk of complications are measurable. Certain high risk surgical patients undergoing cataract surgery with existing conditions, i.e., diabetic retinopathy epiretinal membranes, history of retinal vein occlusion, macular degeneration may be observed for quicker and more controlled recovery.